DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Griese M, Costa S, Linnemann RW. et al.
Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for ≥ 24 Weeks in People With CF and ≥ 1 F508del Allele: Interim Results of an Open-Label Phase Three Clinical Trial.
Am J Respir Crit Care Med 2020;
DOI: 10.1164/rccm.202008-3176LE.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.